# DoW Amyotrophic Lateral Sclerosis Research Program, Clinical Outcomes and Biomarkers Award

Source: https://welltoldgrants.com/grants/ht942526alsrpcoba-dow-amyotrophic-lateral-sclerosis-research-program-clinical/  
Official notice: https://www.grants.gov/search-results-detail/362194

> Defense Health Agency Contracting Activity - DHACA offered grants to any type of organization. It expected to make about 7 awards worth $7.0 million in total. Applications closed on September 30, 2026.

| Field | Value |
|---|---|
| Opportunity number | HT942526ALSRPCOBA |
| Agency | Defense Health Agency Contracting Activity - DHACA |
| Status | Forecast |
| Deadline | September 30, 2026 |
| Award ceiling | not stated |
| Award floor | not stated |
| Expected awards | 7 |
| Total funding | $7.0 million |
| Cost sharing | not required |
| Assistance Listings | 12.420 |

## Who can apply

- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

## What the grant funds

Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Clinical Outcomes and Biomarkers Award (COBA) supports the development and/or validation of clinical outcomes and biomarkers to enrich clinical trials in amyotrophic lateral sclerosis (ALS). Projects can be relevant to a specific therapy, a class of therapeutics, or to a specific ALS subtype (such as a particular genetic mutation) and do not have to broadly apply to all patients. Distinctive Features: To meet the intent of the funding opportunity, applications may address clinical biomarkers and/or clinical outcomes. This may include the identification, development, and/or validation of promising biomarkers for ALS, which may include, but are not limited to susceptibility/risk, diagnostic, monitoring/disease progression, prognostic, predictive, response, or safety biomarkers. Clinical Outcomes projects may focus on the identification, development, and/or validation of clinician-, observer-, or patient-reported, and/or performance outcome measures for ALS. Projects may include the optimization of current outcome measures already in use. Applications may utilize digital health measures, including wearable devices, smart-phone sensors, video or voice recordings, imaging studies, or other devices which record disease-relevant physiological data and/or outcomes. Community Collaboration is an important element of the FY26 ALSRP COBA. Applicants will be expected to articulate how the proposed research question or study design was informed by the ALS lived experience community.

## Questions people ask

### Is HT942526ALSRPCOBA still open?

No. It closed on September 30, 2026. A newer notice is open: HT942526BCRPCREA2, closes November 18, 2026 (11 days left).

### Who can apply for DoW Amyotrophic Lateral Sclerosis Research Program, Clinical Outcomes and Biomarkers Award?

Defense Health Agency Contracting Activity - DHACA accepted applications from any type of organization.

### What is the deadline for DoW Amyotrophic Lateral Sclerosis Research Program, Clinical Outcomes and Biomarkers Award?

Closed September 30, 2026. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### How much funding is available?

About $7.0 million in total across about 7 awards.

### Who has won Military Medical Research and Development grants before?

The largest recipients over five fiscal years were The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The Univeristy of Texas M.D. Anderson Cancer Center, The Johns Hopkins University. The program made 5,470 awards worth $6.9 billion in that time.